4MATHEW J, ASGEIRSSON K S, AGRAWAL A, et al. Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience [ J ] . Eur J Surg Oncol, 2007, 33 (8): 972-976.
5PICKLES M D, LOWRY M, MANTON D J, et al. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators [ J ] . Eur Radiol, 2015, 25(4): 1097- 1106.
6WARREN R M, POINTON L, THOMPSON D, et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis [ J ] . Radiology, 2005, 236(3): 779-788.
7ETXANO J, INSAUST1 L P, ELIZALDE A, et ai. Analysis of the changes induced by hevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy [ J ]. Aeta Radiol, 2015, 56(1 l): 1300-1307,.
8WANG Y, HUANG W, PANICEK D M. Feasibility t using limited-population-based arterial input funtion f)T" pharmacokinetic modeling of esteosarcoma dynamic contrast- enhanced MRI data [ J ] . Magn Reson Med, 2008, 59(5): 1183-1189.
